BioPharma Resources

Drug Trial Radar · NCT06677138

PK Study of Gefurulimab SC in Healthy Chinese Adult Participants

A Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Gefurulimab (ALXN1720) in Healthy Chinese Adults

Last checked: Nov 19, 2026Latest source record: May 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Oct 28, 2024

Primary completion

Mar 19, 2025

Study completion Mar 19, 2025

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to characterize the PK properties of a single dose of gefurulimab in healthy Chinese participants.

Conditions

  • Healthy

Interventions

  • gefurulimabDrug

    Participants will receive gefurulimab subcutaneously (SC).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Serum Concentration (Cmax) of GefurulimabTime frame: Day 1 predose through Day 92 postdose
  2. Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of GefurulimabTime frame: Day 1 predose through Day 92 postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.